(Q36433990)

14 August 2017

1 reference

title

Safety of drug therapies used for weight loss and treatment of obesity (English)

1 reference

14 August 2017

0 references

4

John J McNeil

1 reference

14 August 2017

3

Andrew M Tonkin

1 reference

14 August 2017

Lisa L Ioannides-Demos

series ordinal

1

1 reference

PubMed ID

16569079

14 August 2017

Joseph Proietto

series ordinal

2

1 reference

14 August 2017

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

29

1 reference

14 August 2017

4

1 reference

14 August 2017

277-302

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200629040-00001

14 August 2017

0 references

cites work

Anorectics on trial: a half century of federal regulation of prescription appetite suppressants

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Effects of chronic administration of the amphetamines and other stimulants on behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

The pharmacologic approach to the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Psychotic episode associated with dexfenfluramine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Sibutramine produces dose-related weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Aminorex to fen/phen: an epidemic foretold

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

The fen-phen finale: a study of weight loss and valvular heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

The progression of fenfluramine-associated valvular heart disease assessed by echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Regression and progression of valvulopathy associated with fenfluramine and phentermine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Absence of cardiac valve dysfunction in obese patients treated with sibutramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Cerebral hemorrhage in a patient taking fenfluramine and phentermine for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Possible association of ischemic stroke with phentermine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Intracerebral hemorrhage and phenylpropanolamine use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Ischemic colitis after weight-loss medication

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Sibutramine use associated with reversible hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Stroke associated with ephedrine use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Use of Ephedra-containing products and risk for hemorrhagic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Hepatic injury in 12 patients taking the herbal weight loss AIDS Chaso or Onshido

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Two patients with acute liver injury associated with use of the herbal weight-loss supplement hydroxycut.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Severe hepatotoxicity associated with the dietary supplement LipoKinetix

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629040-00001

Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids

21 January 2018

1 reference

12 December 2020

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

1 reference

12 December 2020

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

1 reference

12 December 2020

A benefit-risk assessment of sibutramine in the management of obesity

1 reference

12 December 2020

A one-year trial to assess the value of orlistat in the management of obesity

1 reference

12 December 2020

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

12 December 2020

Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials

1 reference

12 December 2020

The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers

1 reference

12 December 2020

Plasma phentermine levels, weight loss and side-effects

1 reference

12 December 2020

Amphetamine psychosis and psychotic symptoms

1 reference

12 December 2020

Long-term weight loss: the effect of pharmacologic agents

1 reference

12 December 2020

Asymptomatic mitral and aortic valve disease is seen in half of the patients taking 'phen-fen'.

1 reference

12 December 2020

Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine

1 reference

12 December 2020

Sibutramine. A review of its contribution to the management of obesity.

1 reference

12 December 2020

Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs

1 reference

12 December 2020

Primary pulmonary hypertension

1 reference

12 December 2020

Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour

1 reference

12 December 2020

Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists

1 reference

12 December 2020

Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months

1 reference

12 December 2020

Ephedra/ephedrine: cardiovascular and CNS effects

1 reference

12 December 2020

Overweight, underweight, and mortality. A prospective study of 48,287 men and women

1 reference

12 December 2020

Regression of multivalvular regurgitation after the cessation of fenfluramine and phentermine treatment

1 reference

12 December 2020

Adverse neuropsychiatric events associated with dexfenfluramine and fenfluramine

1 reference

12 December 2020

Relearning the lessons of history: anorexigens and pulmonary hypertension

1 reference

12 December 2020

Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension.

1 reference

12 December 2020

Stroke and phenylpropanolamine use

1 reference

12 December 2020

Pharmacological therapy of obesity: past, present, and future

1 reference

12 December 2020

Risk of valvular heart disease associated with use of fenfluramine

1 reference

12 December 2020

Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials

1 reference

12 December 2020

Valvular heart disease associated with fenfluramine-phentermine

1 reference

12 December 2020

Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine

1 reference

12 December 2020

Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial

1 reference

12 December 2020

Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects

1 reference

12 December 2020

The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent

1 reference

12 December 2020

Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions

1 reference

12 December 2020

Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine

1 reference

12 December 2020

Phenylpropanolamine: an over-the-counter drug causing central nervous system vasculitis and intracerebral hemorrhage. Case report and review

1 reference

12 December 2020

Transient ischemic attack associated with Metabolife 356 use

1 reference

12 December 2020

Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial

1 reference

12 December 2020

Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study

1 reference

12 December 2020

Transient ischemic attacks associated with amfepramone therapy: a case report

1 reference

12 December 2020

Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study

1 reference

12 December 2020

A risk-benefit assessment of anti-obesity drugs

1 reference

12 December 2020

Sibutramine: possible cause of a reversible cardiomyopathy

1 reference

12 December 2020

1 reference

12 December 2020

Phentermine and other monoamine-oxidase inhibitors may increase plasma serotonin when given with fenfluramines

1 reference

12 December 2020

Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis

1 reference

12 December 2020

Biochemistry and behavior: some central actions of amphetamine and antipsychotic drugs

1 reference

12 December 2020

Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997.

1 reference

12 December 2020

Orlistat in the long-term treatment of obesity in primary care settings

1 reference

12 December 2020

Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial

1 reference

12 December 2020

Thyroid hormones and treatment of obesity

1 reference

12 December 2020

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

1 reference

12 December 2020

Pulmonary hypertension and fenfluramine

1 reference

12 December 2020

Pharmacotherapy of obesity: currently marketed and upcoming agents

1 reference

12 December 2020

Primary pulmonary hypertension and fenfluramine use

1 reference

12 December 2020

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

1 reference

12 December 2020

Phentermine resin as an adjunct in medical weight reduction: a controlled, randomized, double-blind prospective study

1 reference

12 December 2020

Therapy of Obesity with Hormones

1 reference

12 December 2020

Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.

1 reference

12 December 2020

Weight management and current options in pharmacotherapy: orlistat and sibutramine

1 reference

12 December 2020

1 reference

12 December 2020

Valvular heart disease in patients taking pergolide

1 reference

12 December 2020

Fenfluramines, idiopathic pulmonary primary hypertension and cardiac valve disorders: facts and artifacts

1 reference

12 December 2020

Dexfenfluramine hydrochloride: an anorexigenic agent

1 reference

12 December 2020

Obesity drugs and the heart

1 reference

12 December 2020

Aminorex, dexfenfluramine, and primary pulmonary hypertension

1 reference

12 December 2020

Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity

1 reference

12 December 2020

Sibutramine-associated psychotic episode

1 reference

12 December 2020

Ruptured retroperitoneal aneurysm in a patient taking phentermine hydrochloride

1 reference

12 December 2020

Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety

1 reference

12 December 2020

Echocardiographic examination of women previously treated with fenfluramine: long-term follow-up of a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

A comparison of sibutramine and dexfenfluramine in the treatment of obesity

1 reference

12 December 2020

Fluoxetine: a randomized clinical trial in the treatment of obesity

1 reference

12 December 2020

Ephedrine as an anorectic: the story of the 'Elsinore pill'

1 reference

12 December 2020

Drug therapy for management of obesity

1 reference

12 December 2020

The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs

1 reference

12 December 2020

Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction

1 reference

12 December 2020

Exacerbation of psychosis by phenylpropanolamine

1 reference

12 December 2020

Detection of aristolochic acid in Chinese phytomedicines and dietary supplements used as slimming regimens

1 reference

12 December 2020

Primary pulmonary hypertension and anorectic drugs

1 reference

12 December 2020

Appetite suppressants and valvular heart disease - a systematic review

1 reference

12 December 2020

Acute interstitial nephritis following treatment with anorectic agents phentermine and phendimetrazine.

1 reference

12 December 2020

Regulatory decisions in a globalised world: the domino effect of phenylpropanolamine withdrawal in Latin America

1 reference

12 December 2020

Rhabdomyolysis in response to weight-loss herbal medicine

1 reference

12 December 2020

Overweight and obesity as determinants of cardiovascular risk: the Framingham experience.

1 reference

12 December 2020

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

1 reference

12 December 2020

Natural history of valvular regurgitation using side-by-side echocardiographic analysis in anorexigen-treated subjects.

1 reference

12 December 2020

Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine

1 reference

12 December 2020

Appetite suppressants and primary pulmonary hypertension in the United Kingdom

1 reference

12 December 2020

1 reference

12 December 2020

Interaction between orlistat and antihypertensive drugs

1 reference

12 December 2020

A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity

1 reference

12 December 2020

Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation

1 reference

12 December 2020

Orlistat: a review of its use in the management of patients with obesity

1 reference

12 December 2020

An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group

1 reference

12 December 2020

Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation

1 reference

12 December 2020

Clinical and basic aspects of an anorexlant, mazindol, as an antlobeslty agent in Japan

1 reference

12 December 2020

Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension

1 reference

12 December 2020

Diethylpropion hydrochloride-induced psychosis

1 reference

12 December 2020

Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults

1 reference

12 December 2020

Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors

1 reference

12 December 2020

Desiccated thyroid in a nutritional supplement.

1 reference

12 December 2020

Increased plasma serotonin in primary pulmonary hypertension

1 reference

12 December 2020

The spread of the obesity epidemic in the United States, 1991-1998

1 reference

12 December 2020

Pharmacological approaches to treating the obese patient

1 reference

12 December 2020

The FDA, regulation, and the risk of stroke

1 reference

12 December 2020

Long-term follow-up of pulmonary hypertension in patients with and without anorectic drug intake.

1 reference

12 December 2020

Endocardial fibrosis associated with fenfluramine-phentermine

1 reference

12 December 2020

Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease

1 reference

12 December 2020

Valvular heart disease associated with fenfluramine-phentermine

1 reference

12 December 2020

Effects of the sibutramine therapy on pulmonary artery pressure in obese patients

1 reference

12 December 2020

Clinical studies with mazindol

1 reference

12 December 2020

International trial of long-term dexfenfluramine in obesity.

1 reference

12 December 2020

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

1 reference

12 December 2020

Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity

1 reference

12 December 2020

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

12 December 2020

Obesity: definitely a growing concern.

1 reference

12 December 2020

Amphetamine psychosis: behavioral and biochemical aspects.

1 reference

12 December 2020

Appetite suppressants and valvular heart disease

1 reference

12 December 2020

Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine

1 reference

12 December 2020

Aminorex and pulmonary hypertension. A review.

1 reference

12 December 2020

Pharmacological therapies for obesity

1 reference

12 December 2020

Exercise-induced syncope associated with QT prolongation and ephedra-free Xenadrine

1 reference

12 December 2020

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

1 reference

12 December 2020

Mortality from primary pulmonary hypertension in the United States, 1979-1996.

1 reference

12 December 2020

Content versus label claims in ephedra-containing dietary supplements

1 reference

12 December 2020

Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias.

1 reference

12 December 2020

Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota

1 reference

12 December 2020

Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials

1 reference

12 December 2020

Dexfenfluramine. An updated review of its therapeutic use in the management of obesity

1 reference

12 December 2020

Topiramate: a new potential pharmacological treatment for obesity

1 reference

12 December 2020

Irreversible pulmonary hypertension after treatment with fenfluramine

1 reference

12 December 2020

The continuing epidemics of obesity and diabetes in the United States

1 reference

12 December 2020

Ischemic stroke after using over the counter products containing ephedra

1 reference

12 December 2020

Comparison of continuous and intermittent anorectic therapy in obesity.

1 reference

12 December 2020

Severe bullous drug eruption due to sibutramine (Reductil).

1 reference

12 December 2020

Dose-effect of fenfluramine use on the severity of valvular heart disease among fen-phen patients with valvulopathy

1 reference

12 December 2020

The age-adjusted mortality rate from primary pulmonary hypertension, in age range 20 to 54 years, did not increase during the years of peak "phen/fen" use

1 reference

12 December 2020

Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports

1 reference

12 December 2020

Pulmonary hypertension and dexfenfluramine

1 reference

12 December 2020

Mitral and aortic valve disease associated with ergotamine therapy for migraine. Report of two cases and review of literature

1 reference

12 December 2020

Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial

1 reference

12 December 2020

Heart Valve Disorders and Appetite-Suppressant Drugs

1 reference

12 December 2020

Orlistat associated with hypertension

1 reference

12 December 2020

Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies

1 reference

12 December 2020

Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study

1 reference

12 December 2020

Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction

1 reference

12 December 2020

Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension

1 reference

12 December 2020

Outcomes of pharmacological and surgical treatment for obesity

1 reference

12 December 2020

High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium

1 reference

12 December 2020

Prescription weight loss pill use among Americans: patterns of pill use and lessons learned from the fen-phen market withdrawal.

1 reference

12 December 2020

A role for potassium channels in smooth muscle cells and platelets in the etiology of primary pulmonary hypertension

1 reference

12 December 2020

Pharmacotherapy for obesity -- do the benefits outweigh the risks?

1 reference

12 December 2020

Psychosis following readministration of diethyl proprion: a possible role for kindling?

1 reference

12 December 2020

Incidence and progression of osteoarthritis in women with unilateral knee disease in the general population: the effect of obesity

1 reference

12 December 2020

Psychotic episode related to phenylpropanolamine and amantadine in a healthy female

1 reference

12 December 2020

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation

1 reference

12 December 2020

The "phen-pro" diet drug combination is not associated with valvular heart disease

1 reference

12 December 2020

Rimonabant adds appetizing choice to slim obesity market

1 reference

12 December 2020

Pharmacotherapy for obesity

1 reference

12 December 2020

Treating obesity: pharmacology of energy expenditure

1 reference

12 December 2020

A controlled study of thyroid analogs in the therapy of obesity

1 reference

12 December 2020

Diethylpropion and psychosis

1 reference

12 December 2020

Pulmonary hypertension and dexfenfluramine

1 reference

12 December 2020

Paradoxical effect of sibutramine on autonomic cardiovascular regulation

1 reference

12 December 2020

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial

1 reference

12 December 2020

Clinical pharmacotherapy for obesity: current drugs and those in advanced development.

1 reference

12 December 2020

Prevalence and Trends in Obesity Among US Adults, 1999-2000

1 reference

12 December 2020

The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study

1 reference

12 December 2020

Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence

1 reference

12 December 2020

Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity

1 reference

12 December 2020

Phenylpropanolamine and associated myocardial injury

1 reference

12 December 2020

Phenylpropanolamine and the risk of hemorrhagic stroke

1 reference

12 December 2020

Anorectic drugs and pulmonary hypertension from the bedside to the bench

1 reference

12 December 2020

High prevalence of fenfluramine-related aortic regurgitation in women with end-stage renal disease secondary to Chinese herb nephropathy

1 reference

12 December 2020

Long-term weight loss with sibutramine: a randomized controlled trial

1 reference

12 December 2020

Delayed onset of pulmonary hypertension associated with an appetite suppressant, mazindol: a case report

1 reference

12 December 2020

Diethylpropion and Paranoid Psychosis

1 reference

12 December 2020

Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi)

1 reference

12 December 2020

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects

1 reference

12 December 2020

Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date

1 reference

12 December 2020

Amphetamine-like reactions to phenylpropanolamine

1 reference

12 December 2020

Valvular heart disease associated with dexfenfluramine

1 reference

12 December 2020

Further cases of valvular heart disease associated with fenfluramine-phentermine

1 reference

12 December 2020

Cardiac murmurs and endocardial fibrosis associated with methysergide therapy

1 reference

12 December 2020

Losing the battle of the bulge: causes and consequences of increasing obesity

1 reference

12 December 2020

Sibutramine may be associated with memory impairment

1 reference

12 December 2020

Three cases of liver injury caused by Sennomotokounou, a Chinese dietary supplement for weight loss.

1 reference

12 December 2020

Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine: a randomized controlled trial

1 reference

12 December 2020

Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine

1 reference

12 December 2020

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

1 reference

12 December 2020

Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment.

1 reference

12 December 2020

10.2165/00002018-200629040-00001

Identifiers

DOI

1 reference

PubMed ID

16569079

Dimensions Publication ID

14 August 2017

0 references

1 reference

PubMed ID

16569079